You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : HEALTHCARE EQUIPMENT & SUPPLIES
  3. INDUSTRY : MEDICAL SPECIALTIES
  4. BIOAFFINITY TECHNOLOGIES INC

BioAffinity Technologies Inc XNAS: BIAF

BioAffinity Technologies Inc Live Share Price Today, Share Analysis and Chart

Download real time

0.29 -0.08 (-21.62%)

90.82% Fall from 52W High

540.6K XNAS Volume

High volume+loss today

XNAS 17 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

BioAffinity Technologies Inc Key Metrics

Select

Market Capitalization

Low in industry
5.2

PE TTM

Negative PE TTM
-0.6

Price to Book

Below industry Median
1.7

Institutional holding current Qtr %

Low in industry
3

Revenue Growth Qtr YoY %

Market Runner Up
687.5

Operating Revenue growth TTM %

Market Leader
2,813.9

Net Profit Qtr Growth YoY %

Below industry Median
12.7

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-16.7

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-84

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-89.1

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-72.2

ROE Annual %

Negative ROE Annual %
-99.8

RoA Annual %

Negative RoA Annual %
-77.8
All financials are in USD Million and price data in USD
VIEW MORE

7

S

15

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


BioAffinity Technologies Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '24Dec '259101112Actual RevenueAvg. Estimate

EPS forecast

Current EPS
-0.8
Avg. Estimate
-0.8
Low Estimate
-0.9
High Estimate
-0.7
Current EPS
Avg. Estimate

Consensus Recommendation

1 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Buy

The consensus recommendation from 1 analyst for BioAffinity Technologies Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

BioAffinity Technologies Inc Stock Analysis

BioAffinity Technologies Inc stock analysis with key metrics, changes, and trends.

BioAffinity Technologies Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$2.53 M687.74%positive

Annual Revenue rose 687.74%, in the last year to $2.53 M. Its sector's average revenue growth for the last fiscal year was 8.73%.

Annual Net Profit$7.94 M9.65%negative

Annual Net Profit fell 9.65% in the last year to $7.94 M. Its sector's average net profit growth for the last fiscal year was 3.62%.

Price to Earning Ratio-0.62-negative

Price to Earning Ratio is -0.62, which is negative.

Stock Price$0.29-84.74%negative

Stock Price fell 84.74% and underperformed its sector by 91.51% in the past year.

Quarterly Revenue$2.35 M687.45%positive

Quarterly Revenue rose 687.45% YoY to $2.35 M. Its sector's average revenue growth YoY for the quarter was 8.57%.

Quarterly Net profit$2 M12.66%positive

Quarterly Net profit rose 12.66% YoY to $2 M. Its sector's average net profit growth YoY for the quarter was 27.31%.

Debt to Equity Ratio0.33-positive

Debt to Equity Ratio of 0.33 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-99.84 %-99.84%negative

Return on Equity(ROE) for the last financial year was -99.84%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding2.38 %-0.27%negative

Mutual Fund Holding decreased by 0.27% in the last quarter to 2.38.

Interest Coverage Ratio-212.23-negative

Interest Coverage Ratio is -212.23, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding2.97 %-0.03%negative

Institutional Holding decreased by 0.03% in the last quarter to 2.97.

VIEW LESS


Loading data..

BioAffinity Technologies Inc - Company Profile

What does BioAffinity Technologies Inc do?

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

BioAffinity Technologies Inc Management structure

All Gross Remunerations are in USD
Mr. Michael Dougherty
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year
Mr. J. Michael Edwards, C.P.A.
Chief Financial Officer and Principal Accounting Officer
-
2024
Gross Remuneration
Year

BioAffinity Technologies Inc Board of directors

All Gross Remunerations are in USD
Mr. Stuart Diamond
Independent Director
105 K
2023
Gross Remuneration
Year
Mr. Peter S. Knight
Independent Director
102.5 K
2023
Gross Remuneration
Year
Mr. Gary Rubin
Independent Director
102.47 K
2023
Gross Remuneration
Year
Mr. Mohsin Y. Meghji
Independent Director
100 K
2023
Gross Remuneration
Year
Mr. Robert A. Anderson
Independent Director
100 K
2023
Gross Remuneration
Year
Mr. Roby P. Joyce, M.D.
Director
25 K
2023
Gross Remuneration
Year

BioAffinity Technologies Inc FAQ

How is BioAffinity Technologies Inc today?
BioAffinity Technologies Inc today is trading in the red, and is down by -21.62% at 0.29.
BioAffinity Technologies Inc is currently trading down -21.62% on an intraday basis. In the past week the stock fell -19.44%. stock has been down -71.57% in the past quarter and fell -84.74% in the past year. You can view this in the overview section.